Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + vinblastine + doxorubicin + cisplatin + panitumumab
- Development stage
- Unknown
- Lead developer
- Unicancer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Methotrexate + vinblastine + doxorubicin + cisplatin + panitumumab is an investigational combination regimen evaluated for the treatment of advanced urothelial carcinoma. This regimen combines the dose-dense or intensified MVAC (dd-MVAC) chemotherapy backbone—comprising methotrexate (an antimetabolite), vinblastine (a microtubule inhibitor), doxorubicin (an anthracycline), and cisplatin (a platinum-based alkylating agent)—with panitumumab, a recombinant human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR). Developed and studied by UNICANCER in the randomized Phase II trial NCT02818725, the combination was specifically tested in patients with KRAS and HRAS wild-type tumors. Clinical findings indicated that the addition of panitumumab to intensified MVAC did not provide a survival benefit and resulted in higher toxicity compared to chemotherapy alone.
- Brand names
- Vectibix
- Other names
- dd-MVAC + panitumumabintensified MVAC + panitumumabI-MVAC + panitumumabintensified methotrexate, vinblastine, doxorubicin and cisplatin + panitumumab
02
Targets
TOP2A (DNA topoisomerase II)EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)DNA
Beyond the preview
Go deeper on methotrexate + vinblastine + doxorubicin + cisplatin + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + vinblastine + doxorubicin + cisplatin + panitumumab.